World Lymphoma Therapeutics Market - Opportunities and Forecasts, 2020-2027
|
LI_181448
|
Pages: NA
|
Mar 2020 |
1475 Views
|
|
|
|
Author(s) :
NA
|
Tables: NA
|
Charts: NA
|
Formats*:
|
|
Lymphoma comprises of a diverse group of blood cancers with different causes and treatment pathways. It is mainly categorized into two forms i.e., Hodgkin Lymphoma and non-Hodgkin Lymphoma (NHL). According to the American Cancer Society (ACS), NHL is one of the most frequently diagnosed cancer in the U.S. that represent 4% of all types of cancers.
The global lymphoma therapeutics market is set to witness an impressive growth, primarily due to high unmet clinical needs associated with the disease and emerging product launches. The NHL therapeutics market is the major market among global lymphoma therapeutics market. The promising drug pipeline and evolving treatment patterns are the factors that would largely drive the market growth. Rising prevalence of lymphoma, increasing funding from different governments, growing awareness and accelerated approvals offered by the regulatory authorities are the other factors that would propel the market growth. On the other hand, premium pricing of drugs, limited reimbursement and looming resistance toward the approved therapies would curtail the market growth.
The patent cliffs of blockbuster drugs would offer lucrative opportunities for new entrants and existing companies. Conversely, the emergence of resistance toward established therapies would remain as a key challenge for the drug innovators.
The market is expected to register substantial growth in mid-term due to the various strategies adopted by the leading industry players. One of the key strategies adopted is co-promotion and commercialization. Recently, EMD Serono entered into an agreement with Pfizer to co-promote its anaplastic lymphoma kinase (ALK) inhibitor Xalkori in the U.S. market.
The report segments the lymphoma drugs market on the basis of cancer type, therapy type and geography. Based on cancer type, the market is segmented into Hodgkin Lymphoma and non-Hodgkin Lymphoma (NHL). On the basis of therapy type, the market is segmented into targeted therapy, chemotherapy, immunotherapy and others. The report covers a geographic breakdown and a detailed analysis of each of the aforesaid segments across North America, Europe, Asia Pacific, and LAMEA.
Comprehensive competitive analysis and profiles of major market players such as F. Hoffmann-La Roche AG, Eli Lilly, Pfizer Inc., Bristol-Myers Squibb (BMS) and others are also provided in the report.
KEY MARKET BENEFITS:
- The report provides an extensive analysis of the current and emerging market trends and dynamics in the global lymphoma drugs market
- Extensive research is done for the market by therapy type, which elucidates the currently used chemotherapy and targeted therapy drugs, evolving role of immunotherapies and in-line extensions opted for existing drugs
- The report covers the detailed quantitative analysis of the current market and estimations through 20142020, which would enable the stakeholders to capitalize on prevailing market opportunities
- The study highlights the competitive landscape and a detailed value chain analysis helps in understanding the competitive environment across various geographies
- A detailed SWOT analysis enables to study the internal environment of the leading companies for strategy formulation
- Competitive intelligence highlights the business practices followed by the leading market players across various geographies
- Owing to an emerging pipeline in the lymphoma drugs market, clinical studies have also been taken into account to better understand the market potential and opportunities
- The lymphoma drugs market scenario is comprehensively analyzed in accordance with the key regions
KEY MARKET SEGMENTS:
The global lymphoma drugs market segmentation is illustrated below:
Lymphoma Drugs Market By Cancer Type
- Hodgkin Lymphoma
- Non-Hodgkin Lymphoma (NHL)
Lymphoma Drugs Market By Therapy Type
- Targeted Therapy
- Approved drugs
- Pipeline drugs
- Chemotherapy
- Approved drugs
- Pipeline drugs
- Immunotherapy
- Others
Lymphoma Drugs Market By Geography
- North America
- U.S.
- Canada
- Mexico
- Europe
- U.K.
- Germany
- France
- Rest of Europe
- Asia-Pacific
- Australia
- Japan
- India
- China
- Rest of Asia Pacific
- LAMEA
- Latin America
- Middle East & Africa
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. TOP PLAYER POSITIONING, 2016
3.4. PATENT ANALYSIS
3.5. MARKET DYNAMICS
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
CHAPTER 4 LYMPHOMA THERAPEUTICS MARKET, BY TYPE
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. HODGKIN LYMPHOMA
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by type
4.2.2.1. Classic Hodgkin lymphoma
4.2.2.1.1. Market size and forecast
4.2.2.2. Nodular lymphocyte predominant Hodgkin lymphoma
4.2.2.2.1. Market size and forecast
4.2.3. Market size and forecast, by region
4.2.4. Market analysis, by country
4.3. NON-HODGKIN LYMPHOMA (NHL)
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by type
4.3.2.1. B-cell lymphomas
4.3.2.1.1. Market size and forecast
4.3.2.2. T-cell lymphomas
4.3.2.2.1. Market size and forecast
4.3.3. Market size and forecast, by region
4.3.4. Market analysis, by country
CHAPTER 5 LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. CHEMOTHERAPY
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. TARGETED THERAPY
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. IMMUNOTHERAPY
5.4.1. Market size and forecast, by type
5.4.1.1. Immune checkpoint inhibitors
5.4.1.1.1. Market size and forecast
5.4.1.2. Chimeric antigen receptor (CAR) T-cell therapy
5.4.1.2.1. Market size and forecast
5.4.1.3. Monoclonal antibodies
5.4.1.3.1. Market size and forecast
5.4.2. Market size and forecast, by region
5.4.3. Market analysis, by country
5.5. RADIATION THERAPY
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country
5.6. STEM CELL/BONE MARROW TRANSPLANTATION
5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by country
5.7. SURGERY
5.7.1. Market size and forecast, by region
5.7.2. Market analysis, by country
CHAPTER 6 LYMPHOMA THERAPEUTICS MARKET, BY END USER
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. HOSPITALS
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. CLINICS
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
6.4. AMBULATORY SURGICAL CENTERS (ASCS)
6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country
CHAPTER 7 MARKET ANALYSIS, BY COUNTRYLYMPHOMA THERAPEUTICS MARKET, BY REGION
7.1. OVERVIEW
7.2. NORTH AMERICA
7.2.1. Key market trends, growth factors and opportunities
7.2.2. North America lymphoma therapeutics market, by country
7.2.2.1. U.S. lymphoma therapeutics market
7.2.2.1.1. U.S. market, by type
7.2.2.1.2. U.S. market, by treatment
7.2.2.1.3. U.S. market, by end user
7.2.2.2. Canada lymphoma therapeutics market
7.2.2.2.1. Canada market, by type
7.2.2.2.2. Canada market, by treatment
7.2.2.2.3. Canada market, by end user
7.2.2.3. Mexico lymphoma therapeutics market
7.2.2.3.1. Mexico market, by type
7.2.2.3.2. Mexico market, by treatment
7.2.2.3.3. Mexico market, by end user
7.2.3. North America lymphoma therapeutics market, by type
7.2.4. North America lymphoma therapeutics market, by treatment
7.2.5. North America lymphoma therapeutics market, by end user
7.3. EUROPE
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Europe lymphoma therapeutics market, by country
7.3.2.1. Germany lymphoma therapeutics market
7.3.2.1.1. Germany market, by type
7.3.2.1.2. Germany market, by treatment
7.3.2.1.3. Germany market, by end user
7.3.2.2. France lymphoma therapeutics market
7.3.2.2.1. France market, by type
7.3.2.2.2. France market, by treatment
7.3.2.2.3. France market, by end user
7.3.2.3. UK lymphoma therapeutics market
7.3.2.3.1. UK market, by type
7.3.2.3.2. UK market, by treatment
7.3.2.3.3. UK market, by end user
7.3.2.4. Italy lymphoma therapeutics market
7.3.2.4.1. Italy market, by type
7.3.2.4.2. Italy market, by treatment
7.3.2.4.3. Italy market, by end user
7.3.2.5. Spain lymphoma therapeutics market
7.3.2.5.1. Spain market, by type
7.3.2.5.2. Spain market, by treatment
7.3.2.5.3. Spain market, by end user
7.3.2.6. Rest of Europe lymphoma therapeutics market
7.3.2.6.1. Rest of Europe market, by type
7.3.2.6.2. Rest of Europe market, by treatment
7.3.2.6.3. Rest of Europe market, by end user
7.3.3. Europe lymphoma therapeutics market, by type
7.3.4. Europe lymphoma therapeutics market, by treatment
7.3.5. Europe lymphoma therapeutics market, by end user
7.4. ASIA-PACIFIC
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Asia-Pacific lymphoma therapeutics market, by country
7.4.2.1. Japan lymphoma therapeutics market
7.4.2.1.1. Japan market, by type
7.4.2.1.2. Japan market, by treatment
7.4.2.1.3. Japan market, by end user
7.4.2.2. China lymphoma therapeutics market
7.4.2.2.1. China market, by type
7.4.2.2.2. China market, by treatment
7.4.2.2.3. China market, by end user
7.4.2.3. Australia lymphoma therapeutics market
7.4.2.3.1. Australia market, by type
7.4.2.3.2. Australia market, by treatment
7.4.2.3.3. Australia market, by end user
7.4.2.4. India lymphoma therapeutics market
7.4.2.4.1. India market, by type
7.4.2.4.2. India market, by treatment
7.4.2.4.3. India market, by end user
7.4.2.5. South Korea lymphoma therapeutics market
7.4.2.5.1. South Korea market, by type
7.4.2.5.2. South Korea market, by treatment
7.4.2.5.3. South Korea market, by end user
7.4.2.6. Rest of Asia-Pacific lymphoma therapeutics market
7.4.2.6.1. Rest of Asia-Pacific market, by type
7.4.2.6.2. Rest of Asia-Pacific market, by treatment
7.4.2.6.3. Rest of Asia-Pacific market, by end user
7.4.3. Asia-Pacific lymphoma therapeutics market, by type
7.4.4. Asia-Pacific lymphoma therapeutics market, by treatment
7.4.5. Asia-Pacific lymphoma therapeutics market, by end user
7.5. LAMEA
7.5.1. Key market trends, growth factors and opportunities
7.5.2. LAMEA lymphoma therapeutics market, by country
7.5.2.1. Brazil lymphoma therapeutics market
7.5.2.1.1. Brazil market, by type
7.5.2.1.2. Brazil market, by treatment
7.5.2.1.3. Brazil market, by end user
7.5.2.2. Saudi Arabia lymphoma therapeutics market
7.5.2.2.1. Saudi Arabia market, by type
7.5.2.2.2. Saudi Arabia market, by treatment
7.5.2.2.3. Saudi Arabia market, by end user
7.5.2.3. South Africa lymphoma therapeutics market
7.5.2.3.1. South Africa market, by type
7.5.2.3.2. South Africa market, by treatment
7.5.2.3.3. South Africa market, by end user
7.5.2.4. Rest of LAMEA lymphoma therapeutics market
7.5.2.4.1. Rest of LAMEA market, by type
7.5.2.4.2. Rest of LAMEA market, by treatment
7.5.2.4.3. Rest of LAMEA market, by end user
7.5.3. LAMEA lymphoma therapeutics market, by type
7.5.4. LAMEA lymphoma therapeutics market, by treatment
7.5.5. LAMEA lymphoma therapeutics market, by end user
CHAPTER 8 COMPANY PROFILES
8.1. F. HOFFMANN-LA ROCHE LTD
8.1.1. Operating business segments
8.1.2. Business performance
8.1.3. Key strategic moves and developments
8.2. ELI LILLY AND CO.
8.2.1. Operating business segments
8.2.2. Business performance
8.2.3. Key strategic moves and developments
8.3. PFIZER INC.
8.3.1. Operating business segments
8.3.2. Business performance
8.3.3. Key strategic moves and developments
8.4. BRISTOL-MYERS SQUIBB CO.
8.4.1. Operating business segments
8.4.2. Business performance
8.4.3. Key strategic moves and developments
8.5. CEPHALON, INC.
8.5.1. Operating business segments
8.5.2. Business performance
8.5.3. Key strategic moves and developments
8.6. CELGENE CORPORATION
8.6.1. Operating business segments
8.6.2. Business performance
8.6.3. Key strategic moves and developments
8.7. GLAXOSMITHKLINE PLC
8.7.1. Operating business segments
8.7.2. Business performance
8.7.3. Key strategic moves and developments
8.8. ACCREDO HEALTH GROUP INC.
8.8.1. Operating business segments
8.8.2. Business performance
8.8.3. Key strategic moves and developments
8.9. BAXTER INTERNATIONAL INC.
8.9.1. Operating business segments
8.9.2. Business performance
8.9.3. Key strategic moves and developments
8.10. BAYER AG
8.10.1. Operating business segments
8.10.2. Business performance
8.10.3. Key strategic moves and developments
We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:
- Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
- Technologically sophisticated and reliable insights through well audited and veracious research methodology
- Sovereign research proceeds that present a tangible depiction of marketplace
With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.
Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, web-casts and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast
Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develops analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth and forecasts
Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:
- Chief executives and VPs of leading corporations specific to industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)
Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.
REQUEST TOC/SAMPLE
Purchase Full Report of
World Lymphoma Therapeutics Market-
Opportunities and Forecasts, 2020-2027
- Online Only
-
$3,456$3,110 - Online cloud access only
- Restricted print, copy, paste & download
- Read only
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Data Pack
-
$3,840$3,456 - Restricted to one authorized user
- One print only
- Available in
Excel - Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Single User
-
$5,370$4,833 - Restricted to one authorized user
- One print only
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Five Users
-
$6,450$5,805 - Limited to five authorized users
- Print upto five copies
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
-
Enterprise
License/PDF -
$8,995$8,096 - Unlimited
within
company/enterprise - Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Library Membership
- $0.00
- Published Content
E-access - Company Profiles
E-access - Newly Added Content Access
- 10 PDF
Downloads - 5 Excel Data
Pack Downloads - 250 Company Profiles PDF Downloads
-
Start reading.
Buy Now
This title and over 12,000+ are available on the Avenue Library. Subscription @ $559 T&C*.
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET VIEW
Targeted market view to provide pertinent information and save time of readers
Get fresh content delivered
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.